...
首页> 外文期刊>European review for medical and pharmacological sciences. >Metabolic responses in non-small cell lung cancer after hypofractionated stereotactic radiotherapy PET and Hypofractionated Radiotherapy
【24h】

Metabolic responses in non-small cell lung cancer after hypofractionated stereotactic radiotherapy PET and Hypofractionated Radiotherapy

机译:超小剂量立体定向放射治疗PET和超小剂量放射治疗后非小细胞肺癌的代谢反应

获取原文

摘要

BACKGROUND: The aim of our study was to evaluate the pattern of local failure after Stereotactic Body Radiotherapy (SBRT) of Non Small Cell Lung Cancer (NSCLC) lesions relating to different type of 18F-FDG Positron Emission Tomography (PET) response. METHODS: Thirteen NSCLC patients for a total of 15 lesions (primary early or locally advanced and metastases) underwent PET before and 6 months after SBRT. Maximum Standard Uptake Value (SUVmax). RESULTS: With a median follow up of 30 months pre- and post-SBRT mean SUV max values were 8.2 (range 14.2-3.7) and 2.4 (range 12.9-0), respectively. No “in field recurrence” was observed while 3 cases of “out field recurrence” occurred as regional nodes progression at 7.8 and 14 months after treatment. Three years overall survival, local control and distant metastases free survival were respectively 66.7%, 63.3% and 44.4%. Actuarial 75% and 53.3% 3-year local control, 60% and 40% 3-years distant metastases free survival were observed for complete and partial PET response, respectively, after SBRT. Thereafter, 60% and 50% 3-year overall survival were observed for complete and partial response. CONCLUSIONS: Clinical results were significantly better for “responder” than “non responder” and for “complete” than “partial response” group. Moreover, our data seem to confirm that a significant subset of patients maintain a low metabolic activity without developing local relapse on longer follow up. Corresponding Author: Stefano Ursino, MD; e-mail: s.ursino@hotmail.it
机译:背景:我们的研究目的是评估与18F-FDG正电子发射断层扫描(PET)反应类型有关的非小细胞肺癌(NSCLC)病变的立体定向放射治疗(SBRT)后的局部衰竭模式。方法:在SBRT之前和之后6个月,对13例NSCLC患者(共计15个病变)(原发性早期或局部晚期转移)进行了PET。最大标准摄取值(SUVmax)。结果:在SBRT前后30个月的中位随访中,SUV最大值分别为8.2(范围14.2-3.7)和2.4(范围12.9-0)。在治疗后7.8个月和14个月,未观察到“野外复发”,而发生3例“野外复发”,原因是区域淋巴结进展。三年总生存率,局部控制率和远处转移免费生存率分别为66.7%,63.3%和44.4%。 SBRT后,对于完全和部分PET反应,分别观察到精算的75%和53.3%的3年局部对照,60%和40%的3年远处转移免费生存。此后,观察到60%和50%的3年总生存率为完全和部分反应。结论:“有反应者”组的临床结果明显优于“无反应者”组,“完全”组优于“部分反应”组。此外,我们的数据似乎证实,大量患者保持较低的代谢活性,而在较长的随访时间中未出现局部复发。通讯作者:Stefano Ursino,MD;电子邮件:s.ursino@hotmail.it

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号